<DOC>
	<DOCNO>NCT00398151</DOCNO>
	<brief_summary>To evaluate change proinflammatory marker ( ltd4 urine ) eosinophil peripheral blood newly initiate montelukast therapy .</brief_summary>
	<brief_title>To Evaluate Inflammatory Markers Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy ( 0476-366 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Allergic rhinitis symptom : sneezing , rhinorrhea , obstruction nasal passage , itchy nose throat , conjunctival Male female outpatient 20 year age old Patients follow sign symptom asthma allergic rhinitis : history cough , wheeze , shortness breath , positive methacholine bronchoprovocation test Active , acute chronic , pulmonary disorder ( besides asthma ) document history , physical examination , chest xray . history anaphylactic hypersensitive study drug Requires oral , intravenous , intramuscular corticosteroid daily routine basis Started immunotherapy within six month prestudy visit and/or dose immunotherapy expect change course study Treated montelukast within 3 month enrollment Unable perform acceptable , reproducible spirometry peak flow measurement Unresolved symptom sign upper respiratory tract infection ( uri ) within 2 week prior visit 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>